Optimized breast MRI functional tumor volume as a biomarker of recurrence-free survival following neoadjuvant chemotherapy

Journal of Magnetic Resonance Imaging

Volumn 40, Issue 2, 2014, Pages 476-482

  Jafri, Nazia F ^a   Newitt, David C ^a   Kornak, John ^b   Esserman, Laura J ^b   Joe, Bonnie N ^a   Hylton, Nola M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

MRI breast functional tumor volume; neoadjuvant chemotherapy; SER PE thresholds

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; TAXANE DERIVATIVE; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST EXAMINATION; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CANCER THERAPY; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONFIDENCE INTERVAL; DISEASE ASSOCIATION; FEMALE; HAZARD RATIO; HUMAN; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RADIOLOGICAL PARAMETERS; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; TUMOR VOLUME; ADJUVANT CHEMORADIOTHERAPY; ADJUVANT THERAPY; BREAST NEOPLASMS; DISEASE FREE SURVIVAL; IMAGE ENHANCEMENT; MIDDLE AGED; PATHOLOGY; PREVENTION AND CONTROL; PROCEDURES; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; THREE DIMENSIONAL IMAGING; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; BREAST NEOPLASMS; CHEMORADIOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMAGE ENHANCEMENT; IMAGING, THREE-DIMENSIONAL; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84904558684     PISSN: 10531807     EISSN: 15222586     Source Type: Journal    
DOI: 10.1002/jmri.24351     Document Type: Article

References (26)

1. Hortobagyi GN,. Progress in systemic chemotherapy of primary breast cancer: an overview. J Natl Cancer Inst Monogr 2001; 72-79.
2. Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B,. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 2001; 30: 96-102.
3. Kuerer HM, Newman LA, Smith TL, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999; 17: 460-469. (Pubitemid 29075229)
4. Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998; 16: 2672-2685. (Pubitemid 28363030)
5. Bonadonna G, Valagussa P, Brambilla C, et al. Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. J Clin Oncol 1998; 16: 93-100. (Pubitemid 28041584)
6. Symmans WF, Peintinger F, Hatzis C, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 2007; 25: 4414-4422. (Pubitemid 350013847)
7. Shin HJ, Kim HH, Ahn JH, et al. Comparison of mammography, sonography, MRI and clinical examination in patients with locally advanced or inflammatory breast cancer who underwent neoadjuvant chemotherapy. Br J Radiol 2011; 84: 612-620.
8. Esserman L, Hylton N, Yassa L, Barclay J, Frankel S, Sickles E,. Utility of magnetic resonance imaging in the management of breast cancer: evidence for improved preoperative staging. J Clin Oncol 1999; 17: 110-119. (Pubitemid 29022384)
9. Chagpar AB, Middleton LP, Sahin AA, et al. Accuracy of physical examination, ultrasonography, and mammography in predicting residual pathologic tumor size in patients treated with neoadjuvant chemotherapy. Ann Surg 2006; 243: 257-264. (Pubitemid 43185446)
10. Gounaris I, Provenzano E, Vallier AL, et al. Accuracy of unidimensional and volumetric ultrasound measurements in predicting good pathological response to neoadjuvant chemotherapy in breast cancer patients. Breast Cancer Res Treat 2011; 127: 459-469.
11. Partridge SC, Vanantwerp RK, Doot RK, et al. Association between serial dynamic contrast-enhanced MRI and dynamic 18F-FDG PET measures in patients undergoing neoadjucant chemotherapy for locally advanced breast cancer. J Magn Reson Imaging 2010; 32: 1124-1131.
12. Dunnwald LK, Gralow JR, Ellis GK, et al. Tumor metabolism and blood flow changes by positron emission tomography: relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer. J Clin Oncol 2008; 26: 4449-4457.
13. Partridge SC, Gibbs JE, Lu Y, et al. MRI measurements of breast tumor volume predict response to neoadjuvant chemotherapy and recurrence-free survival. AJR Am J Roentgenol 2005; 184: 1774-1781. (Pubitemid 40770147)
14. Yi A, Cho N, Im S, et al. Survival outcomes of breast cancer patients who receive neoadjuvant chemotherapy: association with dynamic contrast-enhanced MR imaging with computer-aided evaluation. Radiology 2013 [Epub ahead of print].
15. Heldahl MG, Bathen TF, Rydland J, et al. Prognostic value of pretreatment dynamic contrast-enhanced MR imaging in breast cancer patients receiving neoadjuvant chemotherapy: overall survival predicted from combined time course and volume. Acta Radiol 2010; 51: 604-612.
16. ACR Breast Magnetic Resonance Imaging (MRI) Accreditation Program Requirements, 2011. http://www.acr.org/∼/media/ACR/Documents/Accreditation/ BreastMRI/Requirements. Accessed February 12, 2013.
17. Partridge SC, Heumann EJ, Hylton NM,. Semi-automated analysis for MRI of breast tumors. Stud Health Technol Inform 1999; 62: 259-260.
18. Sahoo S, Lester SC,. Pathology of breast carcinomas after neoadjuvant chemotherapy: an overview with recommendations on specimen processing and reporting. Arch Pathol Lab Med 2009; 133: 633-642.
19. Hylton NM, Blume JD, Bernreuter WK, et al. Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy-results from ACRIN 6657/I-SPY trial. Radiology 2012; 263: 663-672.
20. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216. (Pubitemid 30099779)
21. Li KL, Partridge SC, Joe BN, et al. Invasive breast cancer: predicting disease recurrence by using high-spatial-resolution signal enhancement ratio imaging. Radiology 2008; 248: 79-87.
22. Ah-See ML, Makris A, Taylor NJ, et al. Early changes in functional dynamic magnetic resonance imaging predict for pathologic response to neoadjuvant chemotherapy in primary breast cancer. Clin Cancer Res 2008; 14: 6580-6589.
23. Pickles MD, Lowry M, Manton DJ, et al. Role of dynamic contrast enhanced MRI in monitoring early response of locally advanced breast cancer to neoadjuvant chemotherapy. Breast Cancer Res Treat 2005; 91: 1-10. (Pubitemid 40684933)
24. Wang LC, DeMartini WB, Partridge SC, et al. MRI-detected suspicious breast lesions: predictive values of kinetic features measured by computer-aided evaluation. AJR Am J Roentgenol 2009; 193: 826-831.
25. Partridge SC, Gibbs JE, Lu Y, et al. Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy. AJR Am J Roentgenol 2002; 179: 1193-1199. (Pubitemid 35204372)
26. Li KL, Henry RG, Wilmes LJ, et al. Kinetic assessment of breast tumors using high spatial resolution signal enhancement ratio (SER) imaging. Magn Reson Med 2007; 58: 572-581. (Pubitemid 350154968)